For our last newsletter of 2016, we have some exciting and significant news regarding the Company. On December 15th, Cyprotex PLC was acquired by Evotec AG (www.evotec.com). Our facilities in the UK (Macclesfield and Alderley Park) and the US (Watertown, MA and Kalamazoo, MI) will all function as usual under the Cyprotex brand, and we will continue to offer industry leading in vitro and in silico services and innovations. However, our customers will now have access to Evotec’s integrated and standalone drug discovery services including medicinal chemistry, structural biology and in vitro and in vivo pharmacology services as well as specialist expertise in key therapeutic areas such as neuroscience, pain, metabolic diseases, oncology, immunology and inflammation, respiratory and anti-infectives. The combined entity will allow our customers to benefit from an enhanced portfolio of services managed seamlessly by our expert scientists.
Earlier this year, Cyprotex launched a suite of non-GLP and GLP genotoxicity services. The in vitro chromosomal aberration test was one of these services. Cyprotex Scientist Jessica Sinha presents on this assay, including its significance in a variety of different industries, such as cosmetics and personal care, chemicals, and pharmaceuticals. Causes and mechanisms of chromosomal aberration, its detection, and testing requirements are discussed in detail.
Finally, we would like to thank you for another great year, and wish you a happy and healthy holiday season and a successful year ahead.